IPO Journey
Lakewood-Amedex Biotherapeutics Inc.
IPO Date: May 14, 2026 · 9 filings tracked
Final Offer Terms
Ticker
LABT
Exchange
The Nasdaq Capital Market
Filing Timeline
1
S-1
January 9, 2026
- Developing proprietary Bisphosphocins® technology to combat antibiotic-resistant 'superbugs'.
- Lead candidate Nu-3 targets the significant market for infected diabetic foot ulcers.
2
S-1/A
February 5, 2026
- Developing Bisphosphocins® to combat antibiotic-resistant 'superbugs'
- Lead candidate Nu-3 targeting infected diabetic foot ulcers
3
S-1/A
February 13, 2026
- Focus on high-growth biotech sector targeting antibiotic-resistant 'superbugs'
- Lead candidate Nu-3 addresses significant market for diabetic foot ulcers
4
S-1/A
March 11, 2026
- Developing proprietary Bisphosphocin® technology to combat drug-resistant superbugs.
- Lead candidate Nu-3 (BC-378) targets the significant market for infected diabetic foot ulcers.
5
S-1/A
April 1, 2026
- Developing 'Bisphosphocins' to combat antibiotic-resistant superbugs
- Lead candidate Nu-3 targets diabetic foot ulcer infections
6
S-1/A
April 6, 2026
- Developing Bisphosphocins®, a novel class of medicines targeting antibiotic-resistant 'superbugs'.
- Lead candidate Nu-3 is a specialized gel treatment for diabetic foot ulcers.
7
424B4
Material Update
April 23, 2026
- Developing Bisphosphocins® to combat antibiotic-resistant 'superbugs'
- Proprietary physical attack mechanism targets bacterial cell walls
Changes from previous filing
- ▸ Ticker symbol: LABT
8
S-1
May 1, 2026
- Developing Bisphosphocins®, a novel class of drugs targeting antibiotic-resistant 'superbugs'.
- Lead candidate BC-101 is a topical gel designed for diabetic foot ulcers and skin infections.
Changes from previous filing
- ▸ Exchange: The Nasdaq Capital Market
- ▸ Shares offered: 9,647,726
424B4
Final Pricing
May 14, 2026
- Developing Bisphosphocins® to combat antibiotic-resistant 'superbugs'
- Lead candidate Nu-3 targets the significant market for diabetic foot ulcers
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.